Clinical Study

Fgcl-3019-087- A Phase 3, Randomized, Double-Blind Study Of Pamrevlumab Or Placebo In Combination With Gemcitabine Plus Nab-Paclitaxel (G/Np) As Neoadjuvant Treatment In Patients With Locally Advanced, Unresectable Pancreatic Cance

Posted Date: Dec 17, 2020

  • Investigator: Davendra Sohal
  • Specialties: Cancer, Oncology, Pancreatic Cancer
  • Type of Study: Drug

The main goal of this study is to evaluate the efficacy and safety of neoadjuvant treatment with pamrevlumab or placebo in combination with gemcitabine plus nab-paclitaxel (G/NP) in the treatment of locally advanced, unresectable pancreatic cancer. Each subject may receive up to six cycles of treatment (each treatment cycle is 28 days).


To Be Eligible: Must Have Diagnosis Of Pancreatic Ductal Adenocarcinoma, Ecog 0-1, Measurable Disease, No Prior Chemo Or Radiation For Study Cancer, No Previous Malignancy Within 3 Years, No Uncontrolled Intercurrent Illness, No Major Surgery Within 4 Weeks


Pancreatic Cancer

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.